We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-3.36%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$5.73B
AUM Growth
-$1.02B
Cap. Flow
-$157M
Cap. Flow %
-2.73%
Top 10 Hldgs %
44.42%
Holding
91
New
5
Increased
15
Reduced
36
Closed
16

Top Buys

Rank Stock Value
1
ABSI icon
Absci
ABSI
+$156M
2
IVVD icon
Invivyd
IVVD
+$121M
3
LIVN icon
LivaNova
LIVN
+$88.7M
4
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$44.8M
5
STVN icon
Stevanato
STVN
+$28M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$98.4M
2
ZY
Zymergen Inc. Common Stock
ZY
+$60.9M
3
SLQT icon
SelectQuote
SLQT
+$46.5M
4
CRL icon
Charles River Laboratories
CRL
+$40.1M
5
CI icon
Cigna
CI
+$37.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.61%
2 Consumer Staples 3.39%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OSH
26
DELISTED
Oak Street Health, Inc.
OSH
$79.9M 1.39%
1,878,520
-424,133
-18% -$22.8M
RPTX
27
DELISTED
Repare Therapeutics
RPTX
$67.4M 1.18%
2,567,696
-56,700
-2% -$1.83M
PRTA icon
28
Prothena Corp
PRTA
$479M
$64.2M 1.12%
901,491
-314,166
-26% -$19.5M
ALXO icon
29
ALX Oncology
ALXO
$277M
$63.8M 1.11%
864,435
-49,600
-5% -$3.31M
NVRO
30
DELISTED
NEVRO CORP.
NVRO
$63.2M 1.1%
542,932
-51,800
-9% -$6.78M
ANNX icon
31
Annexon
ANNX
$942M
$62.3M 1.09%
3,349,185
-75,853
-2% -$1.54M
STOK icon
32
Stoke Therapeutics
STOK
$2.04B
$60.6M 1.06%
2,381,958
-76,600
-3% -$2.14M
AKRO
33
DELISTED
Akero Therapeutics
AKRO
$60.1M 1.05%
2,687,444
-117,500
-4% -$2.66M
NGM
34
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$52.7M 0.92%
2,505,118
-287,330
-10% -$6.33M
PLRX icon
35
Pliant Therapeutics
PLRX
$68.7M
$52M 0.91%
3,083,501
-72,900
-2% -$1.55M
ICUI icon
36
ICU Medical
ICUI
$4.38B
$51.9M 0.91%
222,526
-403
-0.2% -$84.5K
SLGC
37
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$49.2M 0.86%
+3,972,270
New +$44.8M
GMAB icon
38
Genmab
GMAB
$20.4B
$49M 0.85%
1,120,388
-107,200
-9% -$4.81M
ELV icon
39
Elevance Health
ELV
$85.5B
$47.5M 0.83%
127,502
+18,701
+17% +$7.11M
UNH icon
40
UnitedHealth
UNH
$353B
$47.2M 0.82%
120,710
+26,245
+28% +$10.9M
IMGN
41
DELISTED
Immunogen Inc
IMGN
$46.8M 0.82%
8,258,345
-622,600
-7% -$3.6M
NUVB icon
42
Nuvation Bio
NUVB
$2.34B
$45.1M 0.79%
4,541,009
– –
EPZM
43
DELISTED
Epizyme, Inc
EPZM
$38.2M 0.67%
7,458,660
-1,056,400
-12% -$6.42M
MDVL
44
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$34.2M 0.6%
234,495
– –
TCRR
45
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$32.5M 0.57%
3,816,709
+580,900
+18% +$8.21M
GRTS
46
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$30.5M 0.53%
2,821,085
+594,879
+27% +$5.41M
STVN icon
47
Stevanato
STVN
$5.74B
$30M 0.52%
+1,187,025
New +$28M
ZYME icon
48
Zymeworks
ZYME
$2.02B
$25.6M 0.45%
882,097
-57,600
-6% -$1.91M
NGNE icon
49
Neurogene
NGNE
$732M
$25.4M 0.44%
175,362
-20,600
-11% -$3.15M
IMTX icon
50
Immatics
IMTX
$1.44B
$25.2M 0.44%
1,941,892
– –
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2021 Portfolio in Review

As of Q3 2021, Redmile Group held 91 positions worth $5.73B, down 15% from $6.76B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Redmile Group's Q3 2021 filing shows 5 new, 15 increased, 36 reduced and 16 closed positions. Its largest new stake was Absci: 8,031,094 shares worth $93.4M. The largest sale was DexCom, an estimated $98.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Financials.

  • Redmile Group's largest Q3 2021 buy was Absci: 8,031,094 shares worth $93.4M.
  • Redmile Group added most to LivaNova in Q3 2021, an estimated $88.7M increase.
  • Redmile Group's biggest Q3 2021 reduction was Seagen Inc. Common Stock, cutting an estimated $28.6M.
  • Redmile Group fully exited DexCom in Q3 2021, selling an estimated $98.4M.
  • Redmile Group's ten largest holdings make up 44% of its $5.73B portfolio in Q3 2021.
  • Redmile Group opened 5 new positions and closed 16 in Q3 2021.
  • Redmile Group's portfolio value fell 15% quarter-over-quarter to $5.73B.

Based on Redmile Group's 13F filing for Q3 2021, filed 15 Nov 2021.